These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35058318)

  • 21. The Food and Drug Administration's Role in Dermatologic Drug Development.
    Lewis FS; Marcus KA
    Dermatol Clin; 2022 Jul; 40(3):249-263. PubMed ID: 35750409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Federal regulations and reimbursement for PET.
    Keppler JS
    J Nucl Med Technol; 2001 Dec; 29(4):173-9; quiz 180-2. PubMed ID: 11756528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Medical Imaging & Technology Alliance conference on research endpoints appropriate for medicare coverage of new PET radiopharmaceuticals.
    Hillman BJ; Frank RA; Abraham BC
    J Am Coll Radiol; 2013 Sep; 10(9):689-94. PubMed ID: 23916799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's Office of Pharmaceutical Quality.
    Fisher AC; Lee SL; Harris DP; Buhse L; Kozlowski S; Yu L; Kopcha M; Woodcock J
    Int J Pharm; 2016 Dec; 515(1-2):390-402. PubMed ID: 27773853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The food and drug administration and molecular imaging agents: potential challenges and opportunities.
    Henderson JA; Alexander BC; Smith JJ
    J Am Coll Radiol; 2005 Oct; 2(10):833-40. PubMed ID: 17411943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA policy on unapproved drug products: past, present, and future.
    Chhabra R; Kremzner ME; Kiliany BJ
    Ann Pharmacother; 2005; 39(7-8):1260-4. PubMed ID: 15956239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology.
    Ning YM; Maher VE
    Urol Oncol; 2015 Mar; 33(3):137-42. PubMed ID: 25613202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Over-the-Counter Drugs: Regulatory Analysis of Warning Letters Between Fiscal Years 2015-2019.
    Bai HK; Ahearn JD; Bartlett MG
    Ther Innov Regul Sci; 2021 Mar; 55(2):426-436. PubMed ID: 33095420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current good manufacturing practices for PET drug products in the United States.
    Swanson D; Graham M; Heinonen TM; Libby P; Mills GQ
    J Nucl Med; 2009 Aug; 50(8):26N-8N. PubMed ID: 19652213
    [No Abstract]   [Full Text] [Related]  

  • 34. Zohydro approval by food and drug administration: controversial or frightening?
    Manchikanti L; Atluri S; Candido KD; Boswell MV; Simopoulos TT; Grider JS; Falco FJ; Hirsch JA
    Pain Physician; 2014; 17(4):E437-50. PubMed ID: 25054396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. INDs for PET molecular imaging probes-approach by an academic institution.
    Mosessian S; Duarte-Vogel SM; Stout DB; Roos KP; Lawson GW; Jordan MC; Ogden A; Matter C; Sadeghi S; Mills GQ; Schelbert HR; Radu CG; Czernin J; Couto M; Phelps ME
    Mol Imaging Biol; 2014 Aug; 16(4):441-8. PubMed ID: 24733693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.
    Bast RC; Thigpen JT; Arbuck SG; Basen-Engquist K; Burke LB; Freedman R; Horning SJ; Ozols R; Rustin GJ; Spriggs D; Wenzel LB; Pazdur R
    Gynecol Oncol; 2007 Nov; 107(2):173-6. PubMed ID: 17950384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of current good manufacturing practices and emission regulations and guidances on the discharge of pharmaceutical chemicals into the environment from manufacturing, use, and disposal.
    Velagaleti R; Burns PK; Gill M; Prothro J
    Environ Health Perspect; 2002 Mar; 110(3):213-20. PubMed ID: 11882470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Data Integrity: History, Issues, and Remediation of Issues.
    Rattan AK
    PDA J Pharm Sci Technol; 2018; 72(2):105-116. PubMed ID: 29158286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.